Rating Rationale
April 01, 2020 | Mumbai
Kwality Pharmaceuticals Limited
Rated amount enhanced
 
Rating Action
Total Bank Loan Facilities Rated Rs.52 Crore (Enhanced from Rs.43 Crore)
Long Term Rating CRISIL BBB-/Stable (Reaffirmed)
Short Term Rating CRISIL A3 (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on the bank facilities of Kwality Pharmaceuticals Limited (KPL).
 
The ratings continue to reflect KPL's established position in the formulations segment and comfortable financial risk profile. These strengths are partially offset by moderate scale and working capital-intensive operations.

Analytical Approach

CRISIL has consolidated the business and financial risk profiles of KPL and its wholly owned subsidiary, Kwality Pharmaceuticals Africa LDA (KPLM; Mozambique) as KPL is the sole shareholder in KPLM and it has significant control over the company along with business synergies. 

Key Rating Drivers & Detailed Description
Strengths:
* Established player in the formulations segment: Over the past three decades, KPL has developed a diverse portfolio of more than 2,000 drugs in the form of tablets, capsules, small volume liquid injections, liquid syrups, dry syrups, dry injections, dental cartridges, and suppositories. It has also added new products such as anti-cancer drugs and penicillin antibiotics. Furthermore, clientele is diverse, with domestic sales having contributed around 49% of total turnover in fiscal 2019, exports 48%, and sales through subsidiary 3%.
 
* Comfortable financial risk profile: Gearing was healthy at 0.81 time as on March 31, 2019, and is expected to remain below 1 time over the medium term on account of a comfortable networth. However, capital expenditure (capex), if any, and its funding mix will remain key rating sensitivity factors. Debt protection metrics are above average.
 
Weaknesses:
* Working capital-intensive operations: Gross current assets were 165 days as on March 31, 2019, due to stretched receivables of 84 days.
 
* Moderate scale of operations:
Intense competition continues to constrain scalability: revenue was moderate at Rs 166.70 crore in fiscal 2019. Although revenue grew 21% year-on-year in fiscal 2019 and is expected to improve over the medium term, backed by higher demand and expansion in the export market, scale should remain moderate.
Liquidity Adequate

Net cash accrual is expected at Rs 8.7-10.2 crore per annum in fiscals 2020 and 2021 against moderate debt repayment of Rs 2.42-3.22 crore. Bank limit utilisation averaged 86% over the 12 months through February 2020. Current ratio was 1.24 times as on March 31, 2019.

Outlook: Stable

CRISIL believes KPL will continue to benefit from the established presence and its improving revenue and operating margins. 

Rating Sensitivity factors
Upward factors
* Improvement in operating income by more than 20% and in operating margin by 200 basis points
* Increase in cash accrual and reduction in working capital cycle
 
Downward factors
* Decline in operating income by more than 15% from fiscal 2019 level and fall in operating profitability from fiscal 2019 level
* Larger-than-expected debt-funded capex weakening financial risk profile
About the Company

Set up in 1980 as a partnership firm and reconstituted as a private limited company in 1983, KPL manufactures formulations in the form of injectables, tablets, capsules, and syrups. It has one unit each in Amritsar (Punjab) and Kangra (Himachal Pradesh), with capacity to produce 3.5 million and 8.5 million tablet per day, respectively. The Kangra unit commenced production in October 2008. KPL is listed on Bombay Stock Exchange Ltd (BSE).
 
Kwality Pharmaceuticals Africa LDA (Mozambique) is a wholly owned subsidiary.

Key Financial Indicators - Consolidated
Particulars Unit 2019 2018
Revenue Rs cr 166.7 137.7
Profit after tax Rs cr 7.56 4.04
PAT margin % 4.5 2.9
Adjusted debt/adjusted networth Times 0.81 0.95
Interest coverage Times 7.1 5.6

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue size
(Rs cr)
Rating assigned
with outlook
NA Cash Credit NA NA NA 16 CRISIL BBB-/Stable
NA Letter of Credit NA NA NA 6 CRISIL A3
NA Term Loan NA NA Mar-23 6 CRISIL BBB-/Stable
NA Pre Shipment Credit NA NA NA 2.0 CRISIL A3
NA Capex Letter of Credit NA NA NA 4.0 CRISIL A3
NA Foreign Bill Purchase NA NA NA 4.88 CRISIL BBB-/Stable
NA Proposed Long Term Bank Loan Facility NA NA NA 13.12 CRISIL BBB-/Stable
 
Annexure - List of entities consolidated
Name of entities Extent of Consolidation Rationale for Consolidation
Kwality Pharmaceuticals Ltd 100% consolidation Kwality Pharmaceuticals Africa LDA (Mozambique) is a wholly owned subsidiary of KPL
Kwality Pharmaceuticals Africa LDA (Mozambique) 100% consolidation Kwality Pharmaceuticals Africa LDA (Mozambique) is a wholly owned subsidiary of KPL
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  42.00  CRISIL BBB-/Stable/ CRISIL A3      28-06-19  CRISIL BBB-/Stable/ CRISIL A3  20-03-18  CRISIL BB+/Positive/ CRISIL A4+      CRISIL BB+/Stable/ CRISIL A4+ 
            22-01-19  CRISIL BBB-/Stable/ CRISIL A3           
Non Fund-based Bank Facilities  LT/ST  10.00  CRISIL A3      28-06-19  CRISIL A3  20-03-18  CRISIL A4+      CRISIL A4+ 
            22-01-19  CRISIL A3           
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Capex Letter of Credit 4 CRISIL A3 Capex Letter of Credit 4 CRISIL A3
Cash Credit 16 CRISIL BBB-/Stable Cash Credit 16 CRISIL BBB-/Stable
Foreign Bill Purchase 4.88 CRISIL BBB-/Stable Foreign Bill Purchase 4.88 CRISIL BBB-/Stable
Letter of Credit 6 CRISIL A3 Letter of Credit 6 CRISIL A3
Pre Shipment Credit 2 CRISIL A3 Long Term Loan 4 CRISIL BBB-/Stable
Proposed Long Term Bank Loan Facility 13.12 CRISIL BBB-/Stable Pre Shipment Credit 2 CRISIL A3
Term Loan 6 CRISIL BBB-/Stable Term Loan 6.12 CRISIL BBB-/Stable
Total 52 -- Total 43 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Approach to Recognising Default
CRISILs Bank Loan Ratings
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt
The Rating Process

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Himank Sharma
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2152
Himank.Sharma@crisil.com


Kishan Gupta
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2177
Kishan.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL